Watch as big pharma is looking for therapies in respiratory diseases and lung. Eevn though this is in another indication big pharma wants in on novel therapies for lung and respiratory drugs. They will eventually also come after INSM imo....
AstraZeneca (AZN.L) is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
The acquisition of the privately held company secures AstraZeneca a position in the emerging market for a new class of lung treatments known as LABA/LAMA drugs that promise improved patient compliance and disease control, without steroids.
Some industry analysts believe that LABA/LAMA inhalers are set to dominate future therapy for chronic obstructive pulmonary disease (COPD), which causes debilitating breathlessness and affects an estimated 210 million people worldwide.
Buying Redwood City, California-based Pearl fills a gap in AstraZeneca's respiratory portfolio, although it will still be behind rivals including GlaxoSmithKline (GSK.L) and Novartis (NOVN.VX) in the race to develop the new type of inhaled drug.